Red Light Holland to rebrand and change name after acquiring Filament Health, focusing on psychedelic drug development.

Red Light Holland announced plans to rebrand and change its company name following its acquisition of Filament Health. This move reflects the company's strategic shift toward a science-driven pharmaceutical platform specializing in regulated psychedelic medicines, including the clinical development of PEX010, a botanical psilocybin drug candidate. The name change will be voted on by shareholders at the Annual General and Special Meeting on May 11, 2026. The rebranding aims to better represent the company's expanded operations in clinical research, GMP manufacturing, and FDA-aligned drug development across multiple business segments.